Purpose: To assess the rate of Infectious Endophthalmitis after anti-vascular endothelial growth factor injection, and to evaluate incidence of infection rate in clinic-based setting. Method: A prospective study was conducted under aseptic clinical conditions at the Ophthalmology department, Polyclinic Hospital in order to assess occurrence of infective endophthalmitis amongst patients who were injected with intravitreal Bevacizumab (Avastin). All patients were consecutively treated by a single surgeon with Intravitreal Bevacizumab using aseptic technique and sourced from the same supplier over a three-year period from January 2019 to December 2021. Results: This is a recent advancement for the cure of one of four clinical indications; Diabetic Retinopathy found in 58% of studied patients, Retinal vein occlusion found in 12% of studied patients, Vitreous hemorrhage found in 23% of studied patients and Age-Related Macular Degeneration found in 7% of studied patients. Total number of patients included in the study were 500. During this period only one patient developed Infective Endophthalmitis who presented within 48 hours and was treated accordingly. Conclusion: No increase in Infective Endophthalmitis was observed when administering Anti Vascular Endothelial Growth Factor (anti-VEGF); Avastin in clinical settings under sterile conditions.